VSTM 241220 11.00P (VSTM241220P11000) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

VSTM241220P11000

Watchlist

0.00
0.000.00%

15min DelayClose Dec 20 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Citi Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $7
Moomoo NewsDec 20 13:31 ET · Ratings
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $9
Moomoo NewsDec 20 13:31 ET · Ratings
H.C. Wainwright Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $7
Moomoo NewsDec 20 13:31 ET · Ratings
Analysts Conflicted on These Healthcare Names: Verastem (VSTM), Roche Holding AG (OtherRHHVF) and Cabaletta Bio (CABA)
TipRanksDec 20 12:20 ET · Ratings
Express News | Applied Therapeutics Inc - Shoshana Shendelman Steps Down as CEO
ReutersDec 20 07:02 ET
Express News | Applied Therapeutics Appoints John H. Johnson as Executive Chairman
ReutersDec 20 07:00 ET

Comments

Trytosaveabit

Dec 18 06:34

Update

$Verastem (VSTM.US)$ Reuters· 3 mins ago
erastem Oncology Provides a Clinical Update for Ramp 203 Trial in Advanced Kras G12C Mutant Non-Small Cell Lung Cancer! Seen no dose limiting toxicities

Tonyco

Nov 29 13:05

$Verastem (VSTM.US)$
If you had bought on 10/31 my last comment, you'd be up 30% now, grats

Tonyco

Oct 31 22:49

$Verastem (VSTM.US)$
Pretty damn good run so far. I only managed to hop on in Sept.

Jaguar8

Oct 31 15:01

NEWS

$Verastem (VSTM.US)$
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology (VSTM) has completed its rolling New Drug Application (NDA) to the FDA for avutometinib plus defactinibcombination therapy for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The company is seeking accelerated approval and priority review, with a potential FDA ap...